ABUS Cash-Secured Put Strategy
ABUS (Arbutus Biopharma Corp), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
ABUS (Arbutus Biopharma Corp) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $906.7M, a trailing P/E of 5.92, a beta of 0.60 versus the broader market, a 52-week range of 3.31-5.38, average daily share volume of 1.9M, a public-listing history dating back to 2007, approximately 19 full-time employees. These structural characteristics shape how ABUS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.60 indicates ABUS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 5.92 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a cash-secured put on ABUS?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
ABUS snapshot
As of August 14, 2026, spot at $4.67, ATM IV 300.40%, IV rank 73.28%, expected move 86.12%. The cash-secured put on ABUS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this cash-secured put structure on ABUS specifically: ABUS IV at 300.40% is rich versus its 1-year range, which favors premium-selling structures like a ABUS cash-secured put, with a market-implied 1-standard-deviation move of approximately 86.12% (roughly $4.02 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABUS expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABUS should anchor to the underlying notional of $4.67 per share and to the trader's directional view on ABUS stock.
ABUS cash-secured put setup
The ABUS cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABUS at $4.67 on that close, the first option leg uses a $4.44 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABUS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABUS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $4.44 | N/A |
ABUS cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
ABUS cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on ABUS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on ABUS
Cash-secured puts on ABUS earn premium while a trader waits to acquire ABUS stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ABUS.
ABUS thesis for this cash-secured put
The market-implied 1-standard-deviation range for ABUS extends from approximately $0.65 on the downside to $8.69 on the upside. A ABUS cash-secured put lets a trader earn premium while waiting to acquire ABUS at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current ABUS IV rank near 73.28% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on ABUS at 300.40%. As a Healthcare name, ABUS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABUS-specific events.
ABUS cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABUS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABUS alongside the broader basket even when ABUS-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on ABUS carry tail risk when realized volatility exceeds the implied move; review historical ABUS earnings reactions and macro stress periods before sizing. Always rebuild the position from current ABUS chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on ABUS?
- A cash-secured put on ABUS is the cash-secured put strategy applied to ABUS (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With ABUS stock at $4.67 on the most recent close, the strikes shown on this page are snapped to the nearest listed ABUS chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ABUS cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the ABUS cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 300.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABUS cash-secured put?
- The breakeven for the ABUS cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ABUS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 86.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on ABUS?
- Cash-secured puts on ABUS earn premium while a trader waits to acquire ABUS stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning ABUS.
- How does current ABUS implied volatility affect this cash-secured put?
- ABUS ATM IV is at 300.40% with IV rank near 73.28%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.